| 生物活性 |
Cubebin ((-)-Cubebin), a dibenzylbutyrolactone lignan, is an orally active AChE inhibitor that binds the active sites of NF-κB, TNF-α, and TGF-β1 through hydrogen bonding and hydrophobic interactions and blocks key residues to inhibit pro-inflammatory or renal fibrosis-related activities; it enhances p38 MAPK phosphorylation to upregulate tyrosinase gene expression and stimulates melanogenesis by increasing tyrosinase activity, expression, and mRNA levels, alleviates oxidative stress by enhancing endogenous antioxidant enzyme activity and inhibiting lipid peroxidation, modulates lipid metabolism and improves glycemic control, and exerts renal protective effects by reducing the levels of markers of renal injury and improving renal structure; in addition, Cubebin exhibits antibacterial activity, larvicidal activity against Angiostrongylus cantonensis larvae, and no cytotoxicity toward monkey cell lines, human cell lines, or Caenorhabditis elegans, and can be used in research related to diabetic nephropathy, melanoma, colon adenocarcinoma, angiostrongyliasis, Alzheimer's disease (AD), and depression. |
体外研究 (In Vitro) |
Cubebin (2-20 μM; 72 h) 可在小鼠 B16 黑色素瘤细胞中以浓度依赖的方式刺激黑色素生成,在 2、5 和 10 μM 浓度下对细胞增殖无显著影响。 Cubebin (10 μM; 24-96 h) 可增强酪氨酸酶活性,并且在小鼠 B16 黑色素瘤细胞中,从 48 h 开始显著增加细胞内黑色素含量,在 72 h 和 96 h 时达到最高水平。 Cubebin (10 μM; 24-72 h) 可增强小鼠 B16 黑色素瘤细胞中酪氨酸酶蛋白的表达,在作用 48 h 时,其表达量相对于处理前细胞提升至 6.2 倍。 Cubebin (10 μM; 12-48 h) 可上调酪氨酸酶 (tyrosinase)的 mRNA 表达,在小鼠 B16 黑色素瘤细胞中,12 h 时其表达量相对于处理前细胞升高 1.8 倍。 Cubebin (10 μM; 2-12 h) 可在 4-8 h 时显著增强小鼠 B16 黑色素瘤细胞中 p38 MAPK 的磷酸化水平,而对 ERK1/2 或 p70 S6K1 的磷酸化无影响。 Cubebin (2.8-280 μM; 24-72 h) 对 HT29 细胞的作用表现为:在 2.8 μM 和 28 μM 浓度下处理 24、48 或 72 h 时无细胞毒性,但在 280 μM 浓度下处理 24、48 或 72 h 时会诱导显著的细胞毒性 (24 h 时细胞活力下降约 50%)。 Cubebin (50-200 μM; 24 h) 对 Vero 猴肾上皮细胞或 HaCaT 人角质形成细胞无细胞毒性,其作用浓度最高可达 200 μM,因此对广州管圆线虫幼虫具有较高的选择性指数。
Cell Proliferation Assay
| Cell Line: |
murine B16 melanoma cells |
| Concentration: |
2, 5, 10, 20 μM |
| Incubation Time: |
72 h |
| Result: |
Stimulated melanogenesis in a concentration-dependent manner. Significantly increased melanin amount at 2 μM relative to control cells. Showed greater significant increases in melanin amount at 5, 10, and 20 μM relative to control cells. Showed no significant effects on cell proliferation at 2, 5, and 10 μM. Slightly decreased cell proliferation at 20 μM. |
Western Blot Analysis
| Cell Line: |
murine B16 melanoma cells |
| Concentration: |
10 μM |
| Incubation Time: |
24, 48, 72 h |
| Result: |
Enhanced tyrosinase expression to 4.9-fold of pre-treated cells at 24 h. Enhanced tyrosinase expression to 6.2-fold of pre-treated cells at 48 h. Enhanced tyrosinase expression to 1.7-fold of pre-treated cells at 72 h. |
RT-PCR
| Cell Line: |
murine B16 melanoma cells |
| Concentration: |
10 μM |
| Incubation Time: |
12, 24, 48 h |
| Result: |
Increased tyrosinase mRNA expression 1.8-fold relative to pre-treated cells at 12 h. Showed 1.7-fold increases in tyrosinase mRNA expression at 24 and 48 h relative to pre-treated cells. |
Western Blot Analysis
| Cell Line: |
murine B16 melanoma cells |
| Concentration: |
10 μM |
| Incubation Time: |
2, 4, 6, 8, 10, 12 h |
| Result: |
Significantly enhanced phosphorylation of p38 MAPK at 4-8 h after treatment. Showed no effects on the phosphorylation levels of ERK1/2 or p70 S6K1. |
RT-PCR
| Cell Line: |
murine B16 melanoma cells |
| Concentration: |
10 μM |
| Incubation Time: |
12 h |
| Result: |
Increased tyrosinase mRNA expression 1.9-fold relative to pre-treated cells. Showed complete block of this cubebin-induced increase in tyrosinase mRNA expression when co-treated with SB203580. |
|
体内研究 (In Vivo) |
Cubebin (10-20 mg/kg;口服;每日一次;持续 8 周) 可显著改善 Streptozotocin (MS-Q80520) 诱导的糖尿病肾病大鼠的血糖控制、脂质代谢、肾功能、氧化应激水平、炎症标志物水平及肾脏组织病理学改变。 Cubebin (10 mg/kg;口服;单次给药) 可抑制角叉菜胶诱导的大鼠足肿胀达 53%,具有统计学意义的抗炎活性。 Cubebin (10 mg/kg;口服;单次给药) 可抑制 PGE2 诱导的大鼠足肿胀达 20%,具有统计学意义的抗炎活性。 Cubebin (10 mg/kg;口服;单次给药) 可抑制 5-羟色胺诱导的大鼠足肿胀,抑制率达 23%,具有统计学意义的抗炎活性。 Cubebin (10 mg/kg;口服;单次给药) 对角叉菜胶诱导的大鼠腹腔细胞迁移未产生统计学意义的抑制作用,仅观察到 12%的抑制率。 Cubebin (10 mg/kg;口服;单次给药) 可使醋酸诱导的小鼠扭体反应抑制率达 50%,具有统计学意义的外周镇痛活性。 Cubebin (10 mg/kg;口服;单次给药) 可抑制 PGI2 诱导的小鼠扭体反应达 71%,具有统计学意义的外周镇痛活性。 Cubebin (10-40 mg/kg;每日;连续 35 天) 可通过恢复脑内神经递质水平、减轻神经组织损伤及调控肠道菌群组成与功能,显著改善雄性 C57BL/6 小鼠由 CUMS 诱导的抑郁样行为。
| Animal Model: |
Wistar (male, 8-10-week-old, 180 g, Streptozotocin-induced diabetic nephropathy) |
| Dosage: |
10 mg/kg; 20 mg/kg |
| Administration: |
p.o.; daily; 8 weeks |
| Result: |
Significantly reduced fasting blood glucose levels and restored serum insulin levels. Significantly reduced HbA1c levels. Significantly reduced total cholesterol and triglyceride levels, and increased high-density lipoprotein levels. Significantly reduced serum creatinine, blood urea nitrogen, and 24-hour urine volume. Significantly increased kidney superoxide dismutase, catalase, and glutathione reductase activity, and reduced kidney malondialdehyde levels. Significantly reduced kidney tumor necrosis factor-α, interleukin-1β, interleukin-6, nuclear factor-kappa B, and transforming growth factor-β1 levels. Significantly improved renal histopathology, restoring normal glomerular and tubular structures and reducing lesions including glomerular basement membrane thickening, cellular necrosis, interstitial inflammation, and hemorrhage. |
| Animal Model: |
C57BL/6 (male, 6-8 weeks old, 18-22 g, CUMS-induced depression-like behavior) |
| Dosage: |
10 mg/kg; 20 mg/kg; 40 mg/kg |
| Administration: |
i.g.; daily; 35 days |
| Result: |
Significantly increased total distance traveled in the open field test and sucrose preference percentage, and significantly decreased immobility time in the tail suspension test and forced swimming test compared to the model group. Reduced pathological damage to hippocampal and cortical neuronal cells, with restored arrangement, number, and morphology of neurons compared to the model group; significantly increased cortical neuron count in the 40 mg/kg group compared to the model group. Significantly increased norepinephrine (NE) and dopamine (DA) levels in cortical tissue in the 20 mg/kg and 40 mg/kg groups compared to the model group; significantly increased NE levels in hypothalamic tissue in all dose groups, and significantly increased DA levels in hypothalamic tissue in the 20 mg/kg group compared to the model group; significantly increased serotonin (5-HT) levels in cortical tissue in all dose groups compared to the model group. Reversed CUMS-induced gut microbiota alterations, including reduced relative abundance of Clostridium, Dorea, Ruminococcus, Eubacterium, Escherichia, Phascolarctobacterium, Lactobacillus, Roseburia, Coprococcus, Sutterella, Akkermansia, Parabacteroides, and Allobaculum, and increased relative abundance of Prevotella, Dehalobacterium, Flavobacterium, and Blautia compared to the model group. Reversed CUMS-induced dysregulation of gut microbiota metabolic pathways, with restored expression levels of KEGG and COG pathway sequences toward control group levels. |
|